Life Science REIT PLC Cash Flow Conversion Efficiency
Life Science REIT PLC cash flow conversion efficiency. Based on the latest financial reports, Life Science REIT PLC (LABS) has a cash flow conversion efficiency ratio of 0.004x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX958.00K ≈ $116.56 USD) by net assets (GBX233.06 Million ≈ $28.36K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Life Science REIT PLC (2021–2024)
Cash flow conversion efficiency of Life Science REIT PLC from 2021 to 2024. This chart illustrates how Life Science REIT PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Life Science REIT PLC (LABS) stock price for real-time trading data and today's change.
Life Science REIT PLC Cash Flow Conversion Ratio Explained
Life Science REIT PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Life Science REIT PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Life Science REIT PLC ranked by their cash flow conversion efficiency. Also see Life Science REIT PLC (LABS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genprex Inc
NASDAQ:GNPX
|
-0.347x |
|
Hedera Group publ AB
ST:HEGR
|
0.021x |
|
Fintech Chain Ltd
AU:FTC
|
-0.019x |
|
Reach PLC
LSE:RCH
|
0.015x |
|
Drugs Made In America Acquisition Corp. Rights
NASDAQ:DMAAR
|
N/A |
|
Middlefield Canadian Income PCC - Middlefield Canadian Income - GBP PC
LSE:MCT
|
0.005x |
|
Monarca Minerals Inc
V:MMN
|
0.008x |
|
Teneo AI AB
ST:TENEO
|
0.051x |
Annual Cash Flow Conversion Efficiency for Life Science REIT PLC (2021–2024)
The table below shows the annual cash flow conversion efficiency of Life Science REIT PLC from 2021 to 2024. Review LABS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX262.77 Million ≈ $31.97K |
GBX12.92 Million ≈ $1.57K |
0.049x | +83.22% |
| 2023-12-31 | GBX283.75 Million ≈ $34.52K |
GBX7.62 Million ≈ $926.53 |
0.027x | +887.98% |
| 2022-12-31 | GBX319.45 Million ≈ $38.87K |
GBX-1.09 Million ≈ $-132.38 |
-0.003x | -133.75% |
| 2021-12-31 | GBX350.58 Million ≈ $42.66K |
GBX3.54 Million ≈ $430.47 |
0.010x | -- |
About Life Science REIT PLC
Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the Golden Triangle of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter. Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.